Promising schizophrenia drug faces tough competition
European Pharmaceutical Review
NOVEMBER 25, 2022
GlobalData’s report showed LY03010 is expected to launch in the US in 2024. Thus, LY03010 could be more convenient to administer and improve patient compliance by optimising the initial dosing regimen, while ensuring efficacy and safety. If successful, the drug is forecasted to reach sales of $63.5 million in 2031, representing 0.6
Let's personalize your content